Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis

被引:7
作者
Havlicek, Juliane [1 ]
Dachsel, Beatrice [1 ]
Slickers, Peter [1 ]
Andres, Soenke [2 ]
Beckert, Patrick [3 ,4 ]
Feuerriegel, Silke [3 ,4 ]
Niemann, Stefan [3 ,4 ]
Merker, Matthias [3 ,4 ]
Labugger, Ines [1 ]
机构
[1] Alere Technol GmbH, Jena, Germany
[2] Res Ctr Borstel, Natl Reference Ctr Mycobacteria, Borstel, Germany
[3] Res Ctr Borstel, Mol & Expt Mycobacteriol, Borstel, Germany
[4] German Ctr Infect Res, Partner Site Hamburg Lubeck, Borstel, Riems, Germany
基金
比尔及梅琳达.盖茨基金会;
关键词
Mycobacterium tuberculosis; Pyrazinamide resistance; Microarray; LINE PROBE ASSAY; BACTEC MGIT 960; PNCA GENE; SUSCEPTIBILITY; MUTATIONS; CANETTII; COMPLEX; DIFFERENTIATION; IDENTIFICATION; SURVEILLANCE;
D O I
10.1016/j.diagmicrobio.2018.12.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis. PZA-resistance is mainly mediated by mutations in the pncA gene; however the current gold standard is a phenotypic drug susceptibility test requiring a well-adjusted pH-value for reliable results. Our melting curve assay detects a non-wild type genotype in selected pncA regions in at least 3750 gene copies/mL within 2.5 hours. The prototype assay was further evaluated by analyzing 271 Mycobacterium tuberculosis complex isolates from Swaziland originating from a previously published drug resistance survey and including 118 isolates with pncA mutations. Sensitivity was 83% (95% CI 75-89%) and specificity was 100% (95% CI 98-100%). Under consideration of further improvements with regard to the target range our melting curve assay has the potential as a rapid rule-in test for PZA susceptibility (wild type pncA), however false resistant results (mutant pncA, but PZA susceptible) cannot be ruled out completely. (C) 2018 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 47 条
  • [1] Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
    Allix-Beguec, Caroline
    Arandjelovic, Irena
    Bi, Lijun
    Beckert, Patrick
    Bonnet, Maryline
    Bradley, Phelim
    Cabibbe, Andrea M.
    Cancino-Munoz, Irving
    Caulfield, Mark J.
    Chaiprasert, Angkana
    Cirillo, Daniela M.
    Clifton, David
    Comas, Inaki
    Crook, Derrick W.
    De Filippo, Maria R.
    de Neeling, Han
    Diel, Roland
    Drobniewski, Francis A.
    Faksri, Kiatichai
    Farhat, Maha R.
    Fleming, Joy
    Fowler, Philip
    Fowler, Tom A.
    Gao, Qian
    Gardy, Jennifer
    Gascoyne-Binzi, Deborah
    Gibertoni-Cruz, Ana-Luiza
    Gil-Brusola, Ana
    Golubchik, Tanya
    Gonzalo, Ximena
    Grandjean, Louis
    He, Guangxue
    Guthrie, Jennifer L.
    Hoosdally, Sarah
    Hunt, Martin
    Iqbal, Zamin
    Ismail, Nazir
    Johnston, James
    Khanzada, Faisal M.
    Khor, Chiea C.
    Kohl, Thomas A.
    Kong, Clare
    Lipworth, Sam
    Liu, Qingyun
    Maphalala, Gugu
    Martinez, Elena
    Mathys, Vanessa
    Merker, Matthias
    Miotto, Paolo
    Mistry, Nerges
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (15) : 1403 - 1415
  • [2] Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan
    Ando, H.
    Mitarai, S.
    Kondo, Y.
    Suetake, T.
    Sekiguchi, J. -I.
    Kato, S.
    Mori, T.
    Kirikae, T.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (08) : 1164 - 1168
  • [3] Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
    Balabanova, Yanina
    Fiebig, Lena
    Ignatyeva, Olga
    Riekstina, Vija
    Danilovits, Manfred
    Jaama, Kaadri
    Davidaviciene, Edita
    Radiulyte, Birute
    Popa, Christina Marcela
    Nikolayevskyy, Vladyslav
    Drobniewski, Francis
    [J]. THORAX, 2017, 72 (09) : 850 - 852
  • [4] Caminero JA, 2012, EUR RESPIR MONOGR, P154, DOI 10.1183/1025448x.10023511
  • [5] Evolution and transmission of drug-resistant tuberculosis in a Russian population
    Casali, Nicola
    Nikolayevskyy, Vladyslav
    Balabanova, Yanina
    Harris, Simon R.
    Ignatyeva, Olga
    Kontsevaya, Irina
    Corander, Jukka
    Bryant, Josephine
    Parkhill, Julian
    Nejentsev, Sergey
    Horstmann, Rolf D.
    Brown, Timothy
    Drobniewski, Francis
    [J]. NATURE GENETICS, 2014, 46 (03) : 279 - +
  • [6] Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan
    Chiu, Yu-Chi
    Huang, Shiang-Fen
    Yu, Kwok-Woon
    Lee, Yu-Chin
    Feng, Jia-Yih
    Su, Wei-Juin
    [J]. BMC INFECTIOUS DISEASES, 2011, 11
  • [7] Evaluation of Methods for Testing the Susceptibility of Clinical Mycobacterium tuberculosis Isolates to Pyrazinamide
    Cui, Zhenling
    Wang, Jie
    Lu, Junmei
    Huang, Xiaochen
    Zheng, Ruijuan
    Hu, Zhongyi
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (05) : 1374 - 1380
  • [8] Daneau Geraldine, 2016, Int J Mycobacteriol, V5 Suppl 1, pS46, DOI 10.1016/j.ijmyco.2016.10.015
  • [9] Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment
    Driesen, M.
    Kondo, Y.
    de Jong, B. C.
    Torrea, G.
    Asnong, S.
    Desmaretz, C.
    Mostofa, K. S. M.
    Tahseen, S.
    Whitfield, M. G.
    Cirillo, D. M.
    Miotto, P.
    Cabibbe, A. M.
    Rigouts, L.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (01) : 60 - 64
  • [10] Rapid differentiation of "Mycobacterium canettii" from other mycobacterium tuberculosis complex organisms by PCR-Restriction analysis of the hsp65 gene
    Goh, KS
    Legrand, E
    Sola, C
    Rastogi, N
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) : 3705 - 3708